Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

Neuroimaging Biomarkers for Predicting rTMS Response in OCD

A legfontosabb adatok

Ki végzi
Stanford University
Hol
Stanford (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
180 fő, tervezett
Kezdés
2021. jan. 15.
Tervezett befejezés
2025. dec. 15.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Active bilateral DMPFC
  • Active right-sided OFC
A regiszteradat frissítve
2023. április 18.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek
A regiszter összes feltétele (20)A regiszter feltételeinek elrejtése

Ki vehet részt

  • meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for OCD with a moderate level of severity as defined by a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 18
  • stable on Serotonin Re-uptake Inhibitor (SRI) medication for at least 8 weeks prior to (with plans to continue throughout) the study Note: Medications that are known to increase cortical excitability (e.g., buprorion, maprotiline, tricyclic antidepressants, classical antipsychotics) or to have an inhibitory effect on brain excitability (e.g., anti-convulsants, benzodiazepines, and atypical antipsychotics), or any other medications with relative hazard for use in TMS will be allowed upon review of medications and/or motor threshold determination by TMS specialist
  • failed at least 1 prior trial of standard first-line OCD treatment per American Psychological Association (APA) Practice Guidelines (serotonin reuptake inhibitor [SRI] or cognitive behavioral therapy with exposure and response prevention)OR had refused these treatments for individual reasons
  • capacity to provide informed consent
  • ability to tolerate clinical study procedures
  • successfully complete the screening forms at the Stanford Center for Cognitive and Neurobiological Imaging (CNI) without any contraindications

Ki nem vehet részt

  • Planning to commence Cognitive Behavioral Therapy (that includes exposure and response prevention) during the period of the study or have begun Cognitive Behavioral Therapy within 8 weeks prior to enrollment (assessed during baseline by study MD)
  • Positive urine screen for illicit drugs (assessed via urine dipstick if screening appointment was more than 30 days ago) [Exceptions: (1) any prescribed medication that participant is currently taking and (2) positive cocaine metabolite after consumption of coca tea]
  • History of receiving Electroconvulsive Therapy (ECT) (assessed during baseline by study MD)
  • Current bipolar disorder (assessed during baseline if screening appointment was more than 30 days ago - SCID-5 Module D)
  • Current moderate or severe Alcohol Usage Disorder or Substance Usage Disorder (except nicotine and caffeine) according to the DSM-5 criteria (assessed only if screening appointment was more than 12 months ago - SCID-5 Module E)
  • Current eating disorder (assessed during baseline if screening appointment was more than 3 months ago - SCID-5 Module I)
  • History of seizure, having an EEG, stroke, head injury (including neurosurgery), implanted devices, frequent or severe headaches, brain related conditions (e.g., intracranial mass lesions globe injuries, hydrocephalus), illness that caused brain injury or first degree relative with seizure disorder (assessed during screening via medical history assessment and TMS Safety Screen by study MD)
  • Individuals with primary hoarding disorder without a DSM-5 OCD diagnosis (as determined by SCID-5 and YBOCS checklist assessed only if screening appointment was more than 30 days ago)
  • History of any implanted device or psychosurgery (assessed during baseline by study MD)
  • Age of OCD symptom onset >30
  • Current psychosis (re-assessed only if screening appointment was more than 30 days ago - Structured Clinical Interview for DSM-IV (SCID) - 5 Module B)
  • Severe depression [Note: 17-item Hamilton Depression Rating Scale (HDRS-17) must be less or equal to 20 to enter study, assessed during baseline if last assessment was more than 1 week ago]
  • Current active suicidality (as determined by C-SSRS at baseline of 3 or above)
  • Pregnant or nursing females (assessed via urine dipstick if screening appointment was more than 30 days ago)

Alkalmassági kérdőív

Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.

  • Életkor
  • Obsessive-compulsive disorder

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Department of Psychiatry and Behavioral Sciences, Stanford School of MedicineStanford, Egyesült ÁllamokContact: Nick Bassano, MSWRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study evaluates an accelerated schedule of theta-burst stimulation using a Transcranial Magnetic Stimulation (TMS) device for treatment-resistant Obsessive Compulsive Disorder (OCD). In a randomized fashion, half the participants will receive accelerated theta-burst stimulation at the dorsomedial prefrontal cortex (DMPFC), while half will receive accelerated theta-burst stimulation at the right orbitofrontal (rOFC) site.

A vizsgálat 2 csoportja

  • bilateral DMPFCMár használt kezelés, összehasonlításként

    This arm will receive intermittent theta-burst stimulation to bilateral DMPFC site.

    Kezelés: Active bilateral DMPFC

  • right OFCMár használt kezelés, összehasonlításként

    This arm will receive continuous theta-burst stimulation to the right OFC site.

    Kezelés: Active right-sided OFC

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Individualized Neuroimaging Biomarkers for Predicting rTMS Response in OCD
Kérdések a feltételekről
Forrás: NCT04286126: ki vehet részt
A regiszteradat frissítve
2023. április 18.